



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Odulimomab

Cat. No.:	HY-P99765
CAS No.:	159445-64-4
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease ^{[1][2]} .	
In Vitro	Odulimomab inhibits proliferation of T lymphocyte, and cytotoxicity and antibody production of T and Natural Killer (NK) cells in vitro ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Odulimomab (1.5 and 0.75 mg/kg; i.p., 1.5 mg/kg for the first treatment then followed by daily injection of 0.75 mg/kg until sacrifice) shows protective effects against ischemia and reperfusion injury, and also repairs in renal function after transplantation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Cynomolgus Monkeys with renal damage ischemia and kidney autotransplantation ^[1]
	Dosage:	1.5 and 0.75 mg/kg
	Administration:	Intraperitoneal injection; 1.5 mg/kg for the first dose and after pedicle clamping followed by daily injection of 0.75 mg/kg until sacrifice
	Result:	Decreased the creatinine level after ischemia and autotransplantation for 3 days and increased the potassium fraction reabsorption.

REFERENCES

[1]. Martin X, et al. Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. Transplant Proc. 2000 Mar;32(2):481.

[2]. M. Hourmant & J. P. Soullillou. Interest in an anti-LFA-1 monoclonal antibody in the prevention of reperfusion injury in kidney transplantation. Organ Allocation pp 215-223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA